焦宁团队和于晓、孙金鹏团队在糖尿病新靶点发现和治疗领域取得重要进展

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (10): 861-862.

焦宁团队和于晓、孙金鹏团队在糖尿病新靶点发现和治疗领域取得重要进展

北京大学药学院天然药物及仿生药物全国重点实验室

北京大学药学院天然药物及仿生药物全国重点实验室

收稿日期:2023-10-09 修回日期:2023-10-09 接受日期:2023-10-09 出版日期:2023-11-04 发布日期:2023-11-06

The team of Prof. Ning Jiao and the teams of Prof. Xiao Yu and Prof. Jinpeng Sun have made important progress in the discovery and treatment of new targets for diabetes

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

Received:2023-10-09 Revised:2023-10-09 Accepted:2023-10-09 Online:2023-11-04 Published:2023-11-06

摘要/Abstract

摘要：

2023年9月28日, 北京大学药学院院天然药物及仿生药物全国重点实验室焦宁教授团队联合山东大学于晓教授团队、北京大学孙金鹏教授团队在国际著名期刊Nature Metabolism在线发表了题为“Functional screening and rational design of compounds targeting GPR132 to treat diabetes” 的研究论文。

Supporting:

北京大学药学院天然药物及仿生药物全国重点实验室. 焦宁团队和于晓、孙金鹏团队在糖尿病新靶点发现和治疗领域取得重要进展[J]. 中国药学(英文版), 2023, 32(10): 861-862.

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The team of Prof. Ning Jiao and the teams of Prof. Xiao Yu and Prof. Jinpeng Sun have made important progress in the discovery and treatment of new targets for diabetes[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 861-862.